Research

Hormonal

PPARgamma agonists (thiazolidinediones like rosiglitazone) improve insulin sensitivity in obese models by downregulating macrophage-derived inflammatory gene expression in white adipose tissue.

Drugs that activate PPARgamma (like rosiglitazone) work partly by calming inflammation in fat tissue. This suggests that anti-inflammatory strategies might be a valid adjunct to metabolic health management in obesity.

GoodSupportsHIGH confidence
Upon treatment with rosiglitazone, an insulin-sensitizing drug, these macrophage-originated genes are downregulated. ... Our results are consistent with the known anti-inflammation function of TZDs and suggest the possibility that TZDs improve insulin sensitivity at least partially by suppressing the inflammatory events in obese WAT.
Haiyan Xu et al. · Journal of Clinical Investigation · 2003

Why this rating

Clear experimental evidence showing gene downregulation and reduced macrophage numbers after treatment.

Source

Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance

Haiyan Xu et al. · Journal of Clinical Investigation · 2003

DOI 10.1172/jci19451

mechanism_onlyCited 5,832×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →